Discovery of a daunorubicin analogue that exhibits potent antitumor activity and overcomes P-gp-mediated drug resistance

Journal of Medicinal Chemistry

Volumn 49, Issue 3, 2006, Pages 932-941

  Fang, Lanyan ^a   Zhang, Guisheng ^a,b   Li, Chenglong ^a   Zheng, Xincheng ^a   Zhu, Lizhi ^a   Xiao, Jim J ^a   Szakacs, Gergely ^c   Nadas, Janos ^a   Chan, Kenneth K ^a   Wang, Peng George ^a   Sun, Duxin ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b HENAN NORMAL UNIVERSITY   (China)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3' AZIDODAUNORUBICIN; ANTHRACYCLINE ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; AZIDE; CYCLOSPORIN A; DAUNORUBICIN; DAUNORUBICIN DERIVATIVE; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CARDIOTOXICITY; CELL LEVEL; CELL STRAIN K 562; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG RESISTANCE; DRUG SYNTHESIS; DRUG UPTAKE; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; HYDROGEN BOND; LEUKEMIA; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; SURVIVAL RATE; TUMOR XENOGRAFT; WEIGHT REDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; AZIDES; CELL LINE, TUMOR; DAUNORUBICIN; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; MICE; MICE, NUDE; MODELS, MOLECULAR; MOLECULAR CONFORMATION; NEOPLASM TRANSPLANTATION; P-GLYCOPROTEIN; TRANSPLANTATION, HETEROLOGOUS;

EID: 32344444566     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm050800q     Document Type: Article

References (60)

1. Weiss, R. B. The anthracyclines: Will we ever find a better doxorubicin? Semin. Oncol. 1992, 19, 670-86.
2. Arcamone, F.; Bernardi, L.; Giardino, P.; Patelli, B.; Di Marco, A.; Casazza, A. M.; Pratesi, G.; Reggiani, P. Synthesis and antitumor activity of 4-demethoxydaunorubicin, 4-demethoxy-7,9-diepidaunorubicin, and their b anomers. Cancer Treat. Rep. 1976, 60, 829-34.
3. Coukell, A. J.; Faulds, D. Epirubicin. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of breast cancer. Drugs 1997, 53, 453-82.
4. Oki, T. New anthracycline antibiotics. Jpn. J. Antibiot. 1977, 30 Suppl, 70-84.
5. Oki, T.; Shibamoto, N.; Matsuzawa, Y.; Ogasawara, T.; Yoshimoto, A.; Kitamura, I.; Inui, T.; Naganawa, H.; Takeuchi, T.; Umezawa, H. Production of nineteen anthracyclic compounds by Streptomyces galilaeus MA144-M1. J. antibiot. 1977, 30, 683-7.
6. Hori, S.; Shirai, M.; Hirano, S.; Oki, T.; Inui, T.; Tsukagoshi, S.; Ishizuka, M.; Takeuchi, T.; Umezawa, H. Antitumor activity of new anthracycline antibiotics, aclacinomycin-A and its analogs, and their toxicity. Gann = Gan. 1977, 68, 685-90.
7. Oki, T.; Matsuzawa, Y.; Yoshimoto, A.; Numata, K.; Kitamura, I. New antitumor antibiotics aclacinomycins A and B. J. Antibiot. 1975, 28, 830-4.
8. Urnezawa, H.; Takahashi, Y.; Kinoshita, M.; Naganawa, H.; Masuda, T.; Ishizuka, M.; Tatsuta, K.; Takeuchi, T. Tetrahydropyranyl derivatives of daunomycin and adriamycin. J. Antibiot. 1979, 32, 1082-4.
9. Israel, M.; Modest, E. J.; Frei, E., 3rd N-Trifluoroacetyladriamycin-14- valerate, an analog with greater experimental antitumor activity and less toxicity than adriamycin. Cancer Res. 1975, 35, 1365-8.
10. Arcamone, F. Doxorubicin, Anticancer Antibiotics; Medicinal Chemistry Series; Academic Press: New York, 1981; Vol. 17, pp 1-369.
11. Weiss, R. B.; Sarosy, G.; Clagett-Carr, K.; Russo, M.; Leyland-Jones, B. Anthracycline analogs: The past, present, and future. Cancer Chemother. Pharmacol. 1986, 18, 185-97.
12. Kimchi-Sarfaty, C.; Gribar, J. J.; Gottesman, M. M. Functional characterization of coding polymorphisms in the human MDR1 gene using a vaccinia virus expression system. Mol. Pharmacol. 2002, 62, 1-6.
13. Gottesman, M. M.; Fojo, T.; Bates, S. E. Multidrug resistance in cancer: Role of ATP-dependent transporters. Nat. Rev. Cancer 2002, 2, 48-58.
14. Gottesman, M. M.; Ambudkar, S. V. Overview: ABC transporters and human disease. J. Bioenerg. Biomembr. 2001, 33, 453-8.
15. Ambudkar, S. V.; Kimchi-Sarfaty, C.; Sauna, Z. E.; Gottesman, M. M. P-glycoprotein: From genomics to mechanism. Oncogene 2003, 22, 7468-85.
16. Komatani, H.; Kotani, H.; Hara, Y.; Nakagawa, R.; Matsumoto, M.; Arakawa, H.; Nishimura, S. Identification of breast cancer resistant protein/mitoxantrone resistance/placenta-specific, ATP-binding cassette transporter as a transporter of NB-506 and J-107088, topoisomerase I inhibitors with an indolocarbazole structure. Cancer Res. 2001, 61, 2827-32.
17. Hirose, M.; Hosoi, E.; Hamano, S.; Jalili, A. Multidrug resistance in hematological malignancy. J. Med. Invest. 2003, 50, 126-35.
18. di Bartolomeo, S.; Spinedi, A. Differential chemosensitizing effect of two glucosylceramide synthase inhibitors in hepatoma cells. Biochem. Biophys. Res. Commun. 2001, 288, 269-74.
19. Gottesman, M. M. How cancer cells evade chemotherapy: Sixteenth Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res. 1993, 53, 747-54.
20. Kaye, S. B. The multidrug resistance phenotype. Br. J. Cancer 1988, 58 (6), 691-4.
21. Yu, D. K. The contribution of P-glycoprotein to pharmacokinetic drug-drug interactions. J. Clin. Pharmacol. 1999, 39, 1203-11.
22. Yu, D. S.; Chang, S. Y.; Ma, C. P. The correlation of membranous glycoprotein-gp-170, cytoplasmic glutathione and glucose-6-phosphate dehydrogenase levels with multidrug resistance in transitional cell carcinoma cell lines of the urinary tract. J. Urol. 1997, 157, 727-31.
23. Yu, D. S.; Chang, S. Y.; Ma, C. P. The expression of mdr-1-related gp-170 and its correlation with anthracycline resistance in renal cell carcinoma cell lines and multidrug-resistant sublines. Br. J. Urol. 1998, 82, 544-7.
24. Chiou, W. L.; Chung, S. M.; Wu, T. C.; Ma, C. A comprehensive account on the role of efflux transporters in the gastrointestinal absorption of 13 commonly used substrate drugs in humans. Int. J. Clin. Pharmacol. Ther. 2001, 39, 93-101.
25. Singal, P. K.; Li, T.; Kumar, D.; Danelisen, I.; Iliskovic, N. Adriamycin-induced heart failure: Mechanism and modulation. Mol. Cell. Biochem. 2000, 207, 77-86.
26. Monneret, C. Recent developments in the field of antitumor anthracyclines. Eur. J. Med. Chem. 2001, 36, 483-493.
27. Minotti, G.; Menna, P.; Salvatorelli, E.; Cairo, G.; Gianni, L. Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev. 2004, 56, 185-229.
28. Zhang, G.; Fang, L.; Zhu, L.; Sun, D.; Wang, P. G. Syntheses and biological activity of bisdaunorubicins. Bioorg. Med. Chem. 2005, in press.
29. Zhang, G.; Shen, J.; Cheng, H.; Zhu, L.; Fang, L.; Luo, S.; Muller, M. T.; Lee, G. E.; Wei, L.; Du, Y.; Sun, D.; Wang, P. G. Syntheses and biological activities of rebeccamycin analogues with uncommon sugar. J. Med. Chem. 2005, 48, 2600-2611.
30. Arcamone, F.; Animati, F.; Capranico, G.; Lombardi, P.; Pratesi, G.; Manzini, S.; Supino, R.; Zunino, F. New developments in antitumor anthracyclines. Pharmacol. Ther. 1997, 76, 117-124.
31. Arcamone, F. M. From the pigments of the actinomycetes to third generation antitumor anthracyclines. Biochimie 1998, 80, 201-206.
32. Binaschi, M.; Bigioni, M.; Cipollone, A.; Rossi, C.; Goso, C.; Maggi, C. A.; Capranico, G.; Animati, F. Anthracyclines: Selected new developments. Curr. Med. Chem.: Anti-Cancer Agents 2001, 1, 113-130.
33. Arcamone, F.; Animati, F.; Berettoni, M.; Bigioni, M.; Capranico, G.; Casazza, A. M.; Caserini, C.; Cipollone, A.; De Cesare, M.; Franciotti, M.; Lombardi, P.; Madami, A.; Manzini, S.; Monteagudo, E.; Polizzi, D.; Pratesi, G.; Righetti, S. C.; Salvatore, C.; Supino, R.; Zunino, F. Doxorubicin disaccharide analogue: Apoptosis-related improvement of efficacy in vivo. J. Natl. Cancer Inst. 1997, 89, 1217-23.
34. Ishikawa, T.; Akimaru, K.; Kuo, M. T.; Priebe, W.; Suzuki, M. How does the MRP/GS-X pump export doxorubicin? J. Natl. Cancer Inst. 1995, 87, 1639-40.
35. Solary, E.; Ling, Y. H.; Perez-Soler, R.; Priebe, W.; Pommier, Y. Hydroxyrubicin, a deaminated derivative of doxorubicin, inhibits mammalian DNA topoisomerase II and partially circumvents multidrug resistance. Int. J. Cancer 1994, 58, 85-94.
36. Borrel, M. N.; Fiallo, M.; Priebe, W.; Garnier-Suillerot, A. P-glycoprotein-mediated efflux of hydroxyrubicin, a neutral anthracycline derivative, in resistant K562 cells. FEBS Lett. 1994, 356, 287-99.
37. Priebe, W.; Perez-Soler, R. Design and tumor targeting of anthracyclines able to overcome multidrug resistance: A double-advantage approach. Pharmacol. Ther. 1993, 60, 215-34.
38. Priebe, W.; Van, N. T.; Burke, T. G.; Perez-Soler, R. Removal of the basic center from doxorubicin partially overcomes multidrug resistance and decreases cardiotoxicity. Anticancer Drugs 1993, 4, 37-48.
39. Ling, Y. H.; Priebe, W.; Yang, L. Y.; Burke, T. G.; Pommier, Y.; Perez-Soler, R. In vitro cytotoxicity, cellular pharmacology, and DNA lesions induced by annamycin, an anthracycline derivative with high affinity for lipid membranes. Cancer Res 1993, 53, 1583-9.
40. Consoli, U.; Priebe, W.; Ling, Y. H.; Mahadevia, R.; Griffin, M.; Zhao, S.; Perez-Soler, R.; Andreeff, M. The novel anthracycline annamycin is not affected by P-glycoprotein-related multidrug resistance: Comparison with idarubicin and doxorubicin in HL-60 leukemia cell lines. Blood 1996, 88, 633-44.
41. Priebe, W.; Van, N. T.; Burke, T. G.; Perez-Soler, R. Removal of the basic center from doxorubicin partially overcomes multidrug resistance and decreases cardiotoxicity. Anti-Cancer Drugs 1993, 4, 37-48.
42. Gate, L.; Couvreur, P.; Nguyen-Ba, G.; Tapiero, H. N-methylation of anthracyclines modulates their cytotoxicity and pharmacokinetic in wild type and multidrug resistant cells. Biomed. Pharmacother. 2003, 57, 301-308.
43. Priebe, W. A.; Perez-Soler, R. Sugar-modified anthracyclines: A search for drugs able to overcome multidrug resistance. Carbohydr. Drug Des. 1997, 551-578.
44. Ge, M.; Chen, Z.; Onishi, H. R.; Kohler, J.; Silver, L. L.; Kerns, R.; Fukuzawa, S.; Thompson, C.; Kahne, D. Vancomycin derivatives that inhibit peptidoglycan biosynthesis without binding D-Ala-D-Ala. Science 1999, 284, 507-511.
45. Ge, M.; Thompson, C.; Kahne, D. Reconstruction of vancomycin by chemical glycosylation of the pseudoaglycon. J. Am. Chem. Soc. 1998, 120, 11014-11015.
46. Alper, P. B.; Hung, S.-C; Wong, C.-H. Metal catalyzed diazo transfer for the synthesis of azides from amines. Tetrahedron Lett. 1996, 37, 6029-6032.
47. Fazio, F.: Bryan, M. C.; Blixt, O.; Paulson, J. C.; Wong, C.-H. Synthesis of sugar arrays in microtiter plate. J. Am. Chem. Soc. 2002, 124, 14397-14402.
48. Lee, J. K.; Chi, Y. S.; Choi, I. S. Reactivity of acetylenyl-terminated self-assembled monolayers on gold: Triazole formation. Langmuir 2004, 20, 3844-3847.
49. Perez-Balderas, F.; Ortega-Munoz, M.; Morales-Sanfrutos, J.; Hernandez-Mateo, F.; Calvo-Flores, F. G.; Calvo-Asin, J. A.; Isac-Garcia, J.; Santoyo-Gonzalez, F. Multivalent neoglycoconjugates by regiospecific cycloaddition of alkynes and azides using organic-soluble copper catalysts. Org. Lett. 2003, 5, 1951-1954.
50. Gottesman, M. M.; Fojo, T.; Bates, S. E. Multidrug resistance in cancer: Role of ATP-dependent transporters. Nat. Rev. Cancer 2002, 2, 48-58.
51. Reyes, C. L.; Chang, G. Structure of the ABC transporter MsbA in complex with ADP. Vanadate and lipopolysaccharide. Science 2005, 308, 1028-1031.
52. Chang, G. Structure of MsbA from Vibrio cholera: A multidrug resistance ABC transporter homolog in a closed conformation. J. Mol. Biol. 2003, 330, 419-430.
53. Chang, G.; Roth, C. B. Structure of MsbA from E. coli: A homolog of the multidrug resistance ATP binding cassette (ABC) transporters. Science 2001, 293, 1793-1800.
54. Grandjean, F.; Bremaud, L.; Verdier, M.; Robert, J.; Ratinaud, M.-H. Sequential gene expression of P-glycoprotein (P-gp), multidrug resistance-associated protein (MRP) and lung resistance protein: Functional activity of P-gp and MRP present in the doxorubicin-resistant human K562 cell lines. Anti-Cancer Drugs 2001, 12, 247-258.
55. Weiner, S. J.; Kollman, P. A.; Case, D. A.; Singh, U. C.; Ghio, C.; Alagona, G.; Profeta, S., Jr.; Weiner, P. A new force field for molecular mechanical simulation of nucleic acids and proteins. J. Am. Chem. Soc. 1984, 106 (3), 765-84.
56. Morris, G. M.; Goodsell, D. S.; Halliday, R. S.; Huey, R.; Hart, W. E.; Belew, R. K.; Olson, A. J. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J. Comput. Chem. 1998, 19, 1639-1662.
57. Gasteiger, J.; Marsili, M. Iterative partial equalization of orbital electronegativity: A rapid access to atomic charges. Tetrahedron 1980, 36, 3219-22.
58. Arora, A.; Seth, K.; Kalra, N.; Shukla, Y. Modulation of P-glycoprotein-mediated multidrug resistance in K562 leukemic cells by indole-3-carbinol. Toxicol. Appl. Pharmacol 2005, 202, 237-43.
59. Wang, J.; Chen, Z.; Xia, X.; Lu, D.; Xue, J.; Ruan, C. Improvement of combination chemotherapy tolerance by introduction of polycistronic retroviral vector drug resistance genes MGMT and MDR1 into human umbilical cord blood CD34+ cells. Leuk. Res. 2002, 26, 281-8.
60. Cullen, K.; Davey, R.; Davey, M. The drug resistance proteins, multidrug resistance-associated protein and P-glycoprotein, do not confer resistance to Fas-induced cell death. Cytometry 2001, 43, 189-94.